Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biogen Idec's Q1 profit falls on one-time charges and expiring Rituxan royalties

This article was originally published in Scrip

Executive Summary

Biogen Idec's first-quarter income fell by 11% to $217 million owing to one-time charges and the expiry of non-US royalties on the anti-CD20 monoclonal antibody Rituxan (rituximab), which is partnered with Roche. The company also reported only a "modest" increase in the number of patients taking its multiple sclerosis drug Tysabri (natalizumab) during January and February.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts